AceShowbiz | PIC: Ryan Reynolds Visits Sandra Bullock's L.A. Pad Us Magazine Ryan Reynolds was » |
Monday, August 29, 2011
PIC: Ryan Reynolds Visits Sandra Bullock's L.A. Pad - Us Magazine
yqyqynesara.blogspot.com
Saturday, August 27, 2011
Live-streaming ruling favors high school associations - Indianapolis Star
gerazawa.wordpress.com
DailyTech | Live-streaming ruling favors high school associations Indianapolis Star A federal appeals court ruling earlier this week upheld the Wisconsin Interscholastic Athletic Association's ability to sell exclusive rights to live-streaming state tournament games online. The Indiana High School Athletic Association had filed a ... Court: No 1st Amendment right to stream live games Broadcasters Out of Luck in Licensing Dispute Federal appeals court ruling preserves WIAA's right to control live streaming ... |
Thursday, August 25, 2011
Rwanda's Orphanage Free Plan Leaves Children Fearful - Voice of America
dudorovanaapyh.blogspot.com
Rwanda's Orphanage Free Plan Leaves Children Fearful Voice of America August 25, 2011 Rwanda's Orphanage Free Plan Leaves Children Fearful Heather Murdock | Nyundo, Rwanda As part of a plan to make Rwanda "orphanage-free," this central African nation plans to close the doors of its largest and oldest orphanage to ... |
Tuesday, August 23, 2011
Security specialist hired by Metro to improve data security - Nashville Business Journal:
http://mymovierankings.com/spider-man-2-2004
Betty Steele, a certified informationm systemssecurity professional, will recommend changes basec on information collected in a Metro data securitgy audit performed earlier this month by Informationn Technology Services. Dean has also asked Steele to examine the need for an IT securitu and standards board made up ofindustry "While it's unfortunate that it took an inciden at the Election Commission office to bring necessarty attention to this issue, we now have the opportunity to improve the way sensitive information is handleed by Metro, and possibly prevent an even worsr situation like this from occurring in the Dean said.
Steele is an attorney with the law officew of and a member ofthe firm'w business law department. She has served as assistang commissioner for business development for the Tennessee Departmenrt of Economic and Communityg Development and as presidenr of Global Competitiveness an affiliate of the Tennesseew Chamber of Commerceand
Betty Steele, a certified informationm systemssecurity professional, will recommend changes basec on information collected in a Metro data securitgy audit performed earlier this month by Informationn Technology Services. Dean has also asked Steele to examine the need for an IT securitu and standards board made up ofindustry "While it's unfortunate that it took an inciden at the Election Commission office to bring necessarty attention to this issue, we now have the opportunity to improve the way sensitive information is handleed by Metro, and possibly prevent an even worsr situation like this from occurring in the Dean said.
Steele is an attorney with the law officew of and a member ofthe firm'w business law department. She has served as assistang commissioner for business development for the Tennessee Departmenrt of Economic and Communityg Development and as presidenr of Global Competitiveness an affiliate of the Tennesseew Chamber of Commerceand
Sunday, August 21, 2011
Company of the Year: Amid takeover rumors and Carl Icahn, Biogen Idec managed to maintain a steady course in 2008 - Boston Business Journal:
cahijisebi.wordpress.com
Through it all, the company saw revenue and profit rise and emerged as that raresyt ofentities — a Massachusetts basedd biotech with plenty of cash. The company’zs solid performance in such a tumultuous year and its positiobn as the clear leader in its market make it the BostonBusineszs Journal’s Company of the Year for 2009. The Cambridge-based compan posted profit of $783.2 million in 2008, up from $638.w million in 2007. In the first quarter of the company’s net income was $247.6 million, putting the companyy on target for profitsapproaching $1 billion in 2009. The company’e market capitalization May 4 was $13.
47 billion, the second largest of any biotechnologg company based in the Boston afterBiogen Idec’s (Nasdaq: BIIB) performance has been buoyedf by sales of its two multiplee sclerosis drugs, Avonex and Sales of Avonex, Biogen’s best increased 4 percent to $555 million in the firsty quarter of 2009. Revenue for the firsft quarter alsoincluded $279 million from the salees of Rituxan, a treatment for certain B-celp non-Hodgkin’s lymphomas and rheumatoid arthritis.
“We’rs coming off a strong year because we’ve built our businesw on marketing the drugs we alread y have and developing a strong pipelinse forthe future,” Biogeh Chief Financial Officer Paul Clancy said. Sales of Tysabroi increased 44 percentto $165 million in the firstr quarter of 2009 from the same perior one year ago. The companyg also received news April 16 that the had approvesdthe company’s new, higher-yield production process for the manufacturing of Tysabro at the company’s plant in Researcnh Triangle Park in Nortn Carolina.
But the drug has been under considerable scrutiny for several and was pulled from the markeyt for 18 months beginning in 2005 because of a suspected link to the rare braimn infection progressivemultifocal leukoencephalopathy, or PML. Sincwe the drug was reintroduced in July the company has discovered a small number of casexs of PML amongTysabri patients. As recentl y as last month, Biogen Idec disclosed that a sixtu multiple sclerosis patient on Tysabri haddeveloped PML. One patiengt has died from the illness, and five of the six casees are outsidethe U.S.
“We anticipated that there wouldr be this level ofoccurrence — it’s less than the warning on the label,” Clancuy said. The PML rate implied on Tysabri’s labeol is one per 1,000 patients. As of the end of March, aboutt 40,000 patients were using Tysabri andabout 24,900 patientes have received at least one year of Biogen officials say the current rate for patiente taking the drug more than 12 monthws is about one in 4,000.
Analystes say Biogen is the leader in the markeg for treatment of multiple sclerosis a market worthpotentially $10 But that could change: There are two Phasre 3 drugs — one by and the othedr by —that could give Biogeb a run for its money if they prove effectiver against MS, said analyst Eric And news in January that Merck KgAA announced successful Phase 3 trial results of its own multiplee sclerosis drug led to a drop in Biogehn shares. Over the past year, Biogen’se shares have traded between a highof $71.38u last July to a low of $39 in December. They were tradinfg at around $46 earlier this week.
And then there’s Carl The billionaire investor, and Biogen’s largest is scrambling to reshuffle Biogen’s board of directors. Just last Biogen urged shareholders to reject a slate of directors proposed by Icahn and toinsteadd re-elect four of its “Once again, even though Carl Icahn has offered no ideas to enhances shareholder value in the 10 months since last year’es annual meeting, he has announced his plan to launchj a proxy contest in an effort to put his own representative on your board of directors,” Bioge Chairman Bruce Ross and CEO James Mullenb said in a lettet to shareholders.
Biogen Idec’s move sets up a likelgy proxy fight with Icahn atthe company’s June 3 annual meeting. Biogen Idec officialsd also said the companyopposesa Icahn’s proposals to fix the size of its boards at 13 members and to reincorporate the compan y in North Dakota, rather than Delaware wher e it is currently incorporated. In a filinvg with the Securities andExchange Commission, Icahn wrote that North Dakota laws afford shareholdersd more protections “against management entrenchment and would make it easier for thirc parties to successfully bid for the corporation.
” the analyst, said that while Icahh may be a thorn in the side of his actions are unlikely to scare off because “the only major changr Icahn seems to want to make is to rein in researchb and development spending, which is higher than averagr for a company with Biogen’s revenues.” Icahn in 2007 unsuccessfully triedc to engineer the sale of Shareholders instead elected the company’s nominees over his slatew of investors. When asked aboutg the potential showdownwith Icahn, Clancy said, “Our results and our board’s focus speakds for itself. I don’t want to commeng on him.
”
Through it all, the company saw revenue and profit rise and emerged as that raresyt ofentities — a Massachusetts basedd biotech with plenty of cash. The company’zs solid performance in such a tumultuous year and its positiobn as the clear leader in its market make it the BostonBusineszs Journal’s Company of the Year for 2009. The Cambridge-based compan posted profit of $783.2 million in 2008, up from $638.w million in 2007. In the first quarter of the company’s net income was $247.6 million, putting the companyy on target for profitsapproaching $1 billion in 2009. The company’e market capitalization May 4 was $13.
47 billion, the second largest of any biotechnologg company based in the Boston afterBiogen Idec’s (Nasdaq: BIIB) performance has been buoyedf by sales of its two multiplee sclerosis drugs, Avonex and Sales of Avonex, Biogen’s best increased 4 percent to $555 million in the firsty quarter of 2009. Revenue for the firsft quarter alsoincluded $279 million from the salees of Rituxan, a treatment for certain B-celp non-Hodgkin’s lymphomas and rheumatoid arthritis.
“We’rs coming off a strong year because we’ve built our businesw on marketing the drugs we alread y have and developing a strong pipelinse forthe future,” Biogeh Chief Financial Officer Paul Clancy said. Sales of Tysabroi increased 44 percentto $165 million in the firstr quarter of 2009 from the same perior one year ago. The companyg also received news April 16 that the had approvesdthe company’s new, higher-yield production process for the manufacturing of Tysabro at the company’s plant in Researcnh Triangle Park in Nortn Carolina.
But the drug has been under considerable scrutiny for several and was pulled from the markeyt for 18 months beginning in 2005 because of a suspected link to the rare braimn infection progressivemultifocal leukoencephalopathy, or PML. Sincwe the drug was reintroduced in July the company has discovered a small number of casexs of PML amongTysabri patients. As recentl y as last month, Biogen Idec disclosed that a sixtu multiple sclerosis patient on Tysabri haddeveloped PML. One patiengt has died from the illness, and five of the six casees are outsidethe U.S.
“We anticipated that there wouldr be this level ofoccurrence — it’s less than the warning on the label,” Clancuy said. The PML rate implied on Tysabri’s labeol is one per 1,000 patients. As of the end of March, aboutt 40,000 patients were using Tysabri andabout 24,900 patientes have received at least one year of Biogen officials say the current rate for patiente taking the drug more than 12 monthws is about one in 4,000.
Analystes say Biogen is the leader in the markeg for treatment of multiple sclerosis a market worthpotentially $10 But that could change: There are two Phasre 3 drugs — one by and the othedr by —that could give Biogeb a run for its money if they prove effectiver against MS, said analyst Eric And news in January that Merck KgAA announced successful Phase 3 trial results of its own multiplee sclerosis drug led to a drop in Biogehn shares. Over the past year, Biogen’se shares have traded between a highof $71.38u last July to a low of $39 in December. They were tradinfg at around $46 earlier this week.
And then there’s Carl The billionaire investor, and Biogen’s largest is scrambling to reshuffle Biogen’s board of directors. Just last Biogen urged shareholders to reject a slate of directors proposed by Icahn and toinsteadd re-elect four of its “Once again, even though Carl Icahn has offered no ideas to enhances shareholder value in the 10 months since last year’es annual meeting, he has announced his plan to launchj a proxy contest in an effort to put his own representative on your board of directors,” Bioge Chairman Bruce Ross and CEO James Mullenb said in a lettet to shareholders.
Biogen Idec’s move sets up a likelgy proxy fight with Icahn atthe company’s June 3 annual meeting. Biogen Idec officialsd also said the companyopposesa Icahn’s proposals to fix the size of its boards at 13 members and to reincorporate the compan y in North Dakota, rather than Delaware wher e it is currently incorporated. In a filinvg with the Securities andExchange Commission, Icahn wrote that North Dakota laws afford shareholdersd more protections “against management entrenchment and would make it easier for thirc parties to successfully bid for the corporation.
” the analyst, said that while Icahh may be a thorn in the side of his actions are unlikely to scare off because “the only major changr Icahn seems to want to make is to rein in researchb and development spending, which is higher than averagr for a company with Biogen’s revenues.” Icahn in 2007 unsuccessfully triedc to engineer the sale of Shareholders instead elected the company’s nominees over his slatew of investors. When asked aboutg the potential showdownwith Icahn, Clancy said, “Our results and our board’s focus speakds for itself. I don’t want to commeng on him.
”
Thursday, August 18, 2011
Deloitte Touche Tohmatsu Company Profile | Company Information
afanasenkobexa.blogspot.com
Deloitte Touche Tohmatsu is an organization of member firms around the world devoted to excellence in providing professional servicesxand advice, focused on client service through a global strategy executed locally in nearlhy 150 countries. With access to the deep intellectual capitaoof 135,000 people worldwide, Deloitte deliveras services in four professional areas
Deloitte Touche Tohmatsu is an organization of member firms around the world devoted to excellence in providing professional servicesxand advice, focused on client service through a global strategy executed locally in nearlhy 150 countries. With access to the deep intellectual capitaoof 135,000 people worldwide, Deloitte deliveras services in four professional areas
Tuesday, August 16, 2011
Ariz. border immigrant deaths drop 38 pct - UPI.com
soileauifyyfa1786.blogspot.com
USA Today | Ariz. border immigrant deaths drop 38 pct UPI.com A United States Border Patrol vehicle cruises along the primary and secondary fence line on the Tijuana, Mexico border in San Diego, December 20, 2007. The area has been the site of » |
Sunday, August 14, 2011
Heritage Valley Health System reaches deal to enhance electronic medical records system - Pittsburgh Business Times:
loxezop.wordpress.com
The gear allows Heritage’s 150 employes doctors to electronically transmit prescriptionsz and access patient medical recordsx from laptops and handheld reducing errors and streamlining The industry average for buying electronic medical recordr systemsis $10,000 per doctor, although the exact amount of the Heritagr Valley contract was not available. Previously, Heritage Valley received a $661,500 grant throughj health insurance giant to help pay forthe upgrade.
In additiojn to two hospitals, Heritage Valle has two surgery centers, two cancere treatment centers and a numberof community-based diagnosticv and treatment facilities to treat patients from Allegheny, Butler and Lawrence counties, and partw of West Virginia and Ohio. Allscriptzs began helping Heritage developp its electronic recordkeeping systemin 2006. “As an integrated deliverhy network, we’re relying on the Allscripts solutiomn to help us create a single electronic patieny record that will drive greatet integration and improvement incare delivery,” Heritagee President and CEO Norm Mitry said in a prepareds statement.
The gear allows Heritage’s 150 employes doctors to electronically transmit prescriptionsz and access patient medical recordsx from laptops and handheld reducing errors and streamlining The industry average for buying electronic medical recordr systemsis $10,000 per doctor, although the exact amount of the Heritagr Valley contract was not available. Previously, Heritage Valley received a $661,500 grant throughj health insurance giant to help pay forthe upgrade.
In additiojn to two hospitals, Heritage Valle has two surgery centers, two cancere treatment centers and a numberof community-based diagnosticv and treatment facilities to treat patients from Allegheny, Butler and Lawrence counties, and partw of West Virginia and Ohio. Allscriptzs began helping Heritage developp its electronic recordkeeping systemin 2006. “As an integrated deliverhy network, we’re relying on the Allscripts solutiomn to help us create a single electronic patieny record that will drive greatet integration and improvement incare delivery,” Heritagee President and CEO Norm Mitry said in a prepareds statement.
Friday, August 12, 2011
Van Eck(R) Global and Merrill Lynch Enter Agreement Regarding Oil Services ... - MarketWatch (press release)
http://artslit.org/HB_buildcomm_yesand.htm
Van Eck(R) Global and Merrill Lynch Enter Agreement Regarding Oil Services ... MarketWatch (press release) NEW YORK, Aug 12, 2011 (BUSINESS WIRE) -- Van Eck Global and Merrill Lynch & Co., a subsidiary of Bank of America Corporation ("Merrill Lynch"), have entered into an agreement relating to Merrill Lynch-sponsored HOLding Depository ReceiptS ("HOLDRS"). ... |
Tuesday, August 9, 2011
Genzyme closes drug plant due to virus - Jacksonville Business Journal:
http://www.morocco-today.info/Morocco_Textiles_and.html
Investors turned on the company’s stoci shortly after the news wasconfirmed Tuesday, pushing Genzyme’s (Nasdaq: stock down roughly 7 percent to $51.80 a Genzyme is currently working to sanitizee the facility and is collaborating with regulatory agencies as it workzs to resume production. But the companh does not expect the plant to be fully operational untill the endof July. The viruw is called Vesivirus 2117, and company officials say it has not been shownm to causehuman However, the virus is known to interferse with the growth of cells used to producd biologic drugs. Genzyme says the viruas was likely introduced througg a nutrient used in themanufacturing process.
Genzymwe has now confirmed that this viruds was the cause of decline in cell productivity attwo facilities, including the company’s Allston in two previous instances in 2008, which were subsequentlt fully addressed. Genzyme has previousl said that it is currently not making enough of the drugs Cerezymefor Gaucher’s disease and Fabrazymr for Fabry disease, to meet projected global The company is unsured how the virus will affect the Cerezyms production but expects Fabrazyme supply constraints to occur for a limitexd period beginning in September.
The companyu said it will workwith physicians, patiente and regulators to minimize the impact of this “The patients who need these therapies are our said Henri A. Termeer, Genzyme’sx chairman and chief executive “We are confident in the quality of the product produced in Allston and in our ability to resolve the issue affecting the The impact willbe temporary.” Genzymwe identified the virus at the Allstonn plant over the weekend and held a conference call with the
Investors turned on the company’s stoci shortly after the news wasconfirmed Tuesday, pushing Genzyme’s (Nasdaq: stock down roughly 7 percent to $51.80 a Genzyme is currently working to sanitizee the facility and is collaborating with regulatory agencies as it workzs to resume production. But the companh does not expect the plant to be fully operational untill the endof July. The viruw is called Vesivirus 2117, and company officials say it has not been shownm to causehuman However, the virus is known to interferse with the growth of cells used to producd biologic drugs. Genzyme says the viruas was likely introduced througg a nutrient used in themanufacturing process.
Genzymwe has now confirmed that this viruds was the cause of decline in cell productivity attwo facilities, including the company’s Allston in two previous instances in 2008, which were subsequentlt fully addressed. Genzyme has previousl said that it is currently not making enough of the drugs Cerezymefor Gaucher’s disease and Fabrazymr for Fabry disease, to meet projected global The company is unsured how the virus will affect the Cerezyms production but expects Fabrazyme supply constraints to occur for a limitexd period beginning in September.
The companyu said it will workwith physicians, patiente and regulators to minimize the impact of this “The patients who need these therapies are our said Henri A. Termeer, Genzyme’sx chairman and chief executive “We are confident in the quality of the product produced in Allston and in our ability to resolve the issue affecting the The impact willbe temporary.” Genzymwe identified the virus at the Allstonn plant over the weekend and held a conference call with the
Sunday, August 7, 2011
Big Brother 13 Live Feeds: Week 5 Saturday Highlights - Big Brother Network
http://property-canada.com/E2M.html
TVGrapevine.com | Big Brother 13 Live Feeds: Week 5 Saturday Highlights Big Brother Network 10:30 AM BBT â€" Porsche tells Daniele she would nominate JeJo if she wins HoH. 11:10 AM BBT â€" Jeff and Jordan discussing the Veto ceremony. Jeff isn't worried about Jordan getting renominated because Kalia is probably worried about upsetting him a! gain ... 'Big Brother 13' Spoilers: Who Did Kalia Nominate in Week 5? Big Brother 13: HOH Kalia makes her nominations (SPOILERS) Big Brother 13 Week 5 Spoilers: Nominees and POV Winner Revealed! |
Subscribe to:
Posts (Atom)